Abstract
Metastasis to the brain is an increasing complication of solid cancers, associated with high morbidity and mortality. Our understanding of key molecular and cellular determinants of early brain colonization and metastatic growth has significantly increased in the last decade, including crucial interactions with brain blood vessels. In lung adenocarcinoma, an early angiogenic switch appears mandatory for outgrowth beyond a micrometastatic state. This can explain preventive effects of antiangiogenics against brain metastases formation in lung adenocarcinoma, which are suggested by mouse experiments and retrospective analysis of a clinical trial. Interestingly, there is no indication that those preventive effects of antiangiogenics against the formation of macrometastases can be found outside the brain, or in other tumor entities. In established brain macrometastases of various cancers, a growth pattern with strong angiogenic features can frequently been observed. Accordingly, an increasing amount of data speaks for a clinically meaningful activity of antiangiogenics, particularly the anti-VEGF-A antibody bevacizumab, against brain macrometastases of patients. Moreover, the antiedema effects of this class of drugs, including their activity against radionecrosis, make antiangiogenics to useful agents in clinical practice with beneficial effects on neurological deficits and quality of life. This is even true for antiangiogenics like bevacizumab given as single agents without combined chemotherapy. Taken together, there is accumulating evidence that antiangiogenics might have a particularly meaningful role in the prevention and treatment of brain metastases. The lack of prospective randomized trials means that they have to be considered experimental therapies in this situation today. Thus, more robust clinical data are necessary to fully clarify the role of antiangiogenics in brain metastases, a disease where better strategies for prevention and treatment are urgently needed.
Similar content being viewed by others
References
Auperin A et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341(7):476–484
Baek KH et al (2009) Down’s syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459(7250):1126–1130
Batchelor TT et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 110(47):19059–19064
Bennouna J et al (2018) Bevacizumab in combination with platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer with or without brain metastases: a French cohort study (EOLE). Oncology 94(1):55–64
Berghoff AS, Preusser M (2018) Anti-angiogenic therapies in brain metastases. Memo 11(1):14–17
Berghoff AS et al (2014) Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report. Breast Care (Basel) 9(2):134–136
Berghoff AS et al (2015) Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol 41(2):e41–e55
Besse B et al (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16(1):269–278
Besse B et al (2015) Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res 21(8):1896–1903
Bhaskara A, Eng C (2008) Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer 7(1):65–68
Boothe D et al (2013) Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro-Oncology 15(9):1257–1263
Chen BB et al (2016) A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer 16:466
Chevreau C et al (2014) A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 12(1):50–54
Danciu OC et al (2011) Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Med Oncol 29:2619–22
Davis FG et al (2012) Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro-Oncology 14(9):1171–1177
De Braganca KC et al (2010) Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neuro-Oncol 100(3):443–447
Delishaj D et al (2017) Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature. J Clin Med Res 9(4):273–280
DeSantis CE et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64(4):252–271
Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21):4368–4380
Felsberg J et al (2017) THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 19(suppl_6):vi2
Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273–286
Gianni L et al (2013) AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31(14):1719–1725
Goldberg SB et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983
Gore ME et al (2011) Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117(3):501–509
Ilhan-Mutlu A et al (2016) Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther 15(4):702–710
Jain RK et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622
Kienast Y, Winkler F (2010) Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 10(11):1763–1777
Kienast Y et al (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16(1):116–122
Labidi SI et al (2009) Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 9(2):118–121
Levin VA et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495
Lin NU et al (2013) CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res 19(23):6404–6418
Lu YS et al (2015) Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res 21(8):1851–1858
Margolin K et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465
Mathews MS et al (2008) The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol 70(6):649–652
Miles DW et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247
Osswald M et al (2016) Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases. Clin Cancer Res 22(24):6078–6087
Palmieri D et al (2014) Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res 20(10):2727–2739
Preusser M et al (2012) Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123(2):205–222
Reck M et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227–1234
Reck M et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804–1809
Reynolds LE et al (2010) Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome. Nature 465(7299):813–817
Roth P, Wick W, Weller M (2010) Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol 23(6):597–602
Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550
Scholz A et al (2016) Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med 8(1):39–57
Socinski MA et al (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27(31):5255–5261
Soffietti R et al (2017) Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology 19(2):162–174
Steeg PS (2012) Perspective: the right trials. Nature 485(7400):S58–S59
Steeg PS, Camphausen KA, Smith QR (2011) Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11(5):352–363
Stefanou D et al (2016) Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: focus on patients with brain metastases. Oncol Lett 12(6):4635–4642
Su YL, Rau KM (2015) Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma. J Thorac Oncol 10(4):e21–e22
Tawbi HA et al (2018) Combined Nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722–730
Valiente M et al (2018) The evolving landscape of brain metastasis. Trends Cancer 4(3):176–196
Winkler F (2017) Hostile takeover: how tumours hijack pre-existing vascular environments to thrive. J Pathol 242(3):267–272
Winkler F et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553–563
Winkler F, Osswald M, Wick W (2018) Anti-angiogenics: their role in the treatment of glioblastoma. Oncol Res Treat 41(4):181–186
Yamamoto D et al (2012) Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. Onco Targets Ther 5:185–189
Yang Q, Rasmussen SA, Friedman JM (2002) Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359(9311):1019–1025
Acknowledgments
This work was funded by the Deutsche Krebshilfe (German Cancer Aid), Priority Program “Translational Oncology”, #70112507, “Preventive strategies against brain metastases”.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Winkler, F. (2019). Antiangiogenics in Brain Metastases: Perspectives and Experiences. In: Marmé, D. (eds) Tumor Angiogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-31215-6_49-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-31215-6_49-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-31215-6
Online ISBN: 978-3-319-31215-6
eBook Packages: Springer Reference MedicineReference Module Medicine